An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors

Sverre Kjeldsen, Giuseppe Mancia, Roland Schmieder, Michaela Mattheus, Thomas Unger

Research output: Contribution to journalArticle

Abstract

International hypertension guidelines endorse the use of combination therapy to achieve blood pressure control in the majority of patients. Angiotensin AT1 receptor blockers, in combination with diuretics, are among the preferred combinations, with telmisartan plus hydrochlorothiazide (HCTZ) being an effective and well-tolerated combination. This article provides an up-to-date review of the existing data on telmisartan/HCTZ combination for the management of hypertension in patients with additional cardiovascular risk factors, including reports emerging from a number of recent clinical trials and secondary analyses of older trials. The accumulated evidence from clinical trials demonstrates that telmisartan/HCTZ combinations are effective and well tolerated in patients with mild-to-severe hypertension, including subgroups of patients with cardiovascular risk factors such as advanced age, obesity, chronic kidney disease, diabetes mellitus and treatment-resistant hypertension.

Original languageEnglish
Pages (from-to)673-682
Number of pages10
JournalExpert Review of Cardiovascular Therapy
Volume11
Issue number6
DOIs
Publication statusPublished - Jun 2013

Keywords

  • diabetes mellitus
  • high cardiovascular risk
  • hydrochlorothiazide
  • hypertension
  • obesity
  • renal impairment
  • telmisartan

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Fingerprint Dive into the research topics of 'An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors'. Together they form a unique fingerprint.

  • Cite this